Upath enterprise software

Manufactured by Roche

Sourced in Switzerland

UPath enterprise software is a digital pathology solution developed by Roche. It is designed to manage and analyze digital pathology images and data. The software provides tools for image viewing, annotation, and analysis, enabling pathologists and laboratories to work with digital pathology workflows.

Automatically generated - may contain errors

Lab products found in correlation

Ventana dp 200, by Roche (1 mentions)

Spelling variants of this product

UPath (2 citations)

2 protocols using upath enterprise software

Automated HER2 IHC Scoring Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC slides were digitalized using a VENTANA DP200 (Roche Diagnostic International, Rotkreuz, Switzerland) and analyzed using the HER2 4B5 algorithm in the uPath enterprise software (Roche Diagnostic International, Rotkreuz, Switzerland). Three regions of interest (ROI) were selected per slide: two smaller ROIs were placed over separate areas with at least 100 tumor cells (“area 1” and “area 2”), and a large ROI was placed over all tumor tissue on the slide (“area 3”). The mean score of these three areas was calculated and taken to represent the AI-determined HER2 IHC score (Figure 1b). This method was developed in order to minimize ROI- and user-dependent factors in the AI evaluation.

Palm C., Connolly C.E., Masser R., Padberg Sgier B., Karamitopoulou E., Simon Q., Bode B, & Tinguely M. (2023). Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors. Diagnostics, 13(1), 168.

+ Open protocol

+ Expand

Validating HER2 Dual ISH Scoring Algorithm

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 9 pathologists, who were previously qualified to manually evaluate VENTANA HER2 Dual ISH-stained breast cancer specimens for HER2 gene status, participated in the study. Three groups, Screening, Consensus, and Reader pathologists performed specific study activities (Fig. 1) and underwent training specific for the study protocol prior to performing study activities. Reader (pathologists who participated in digital and manual scoring) Pathologists (n=3) received training regarding the use the uPath HER2 Dual ISH IA algorithm. Training for the uPath HER2 Dual ISH IA algorithm was conducted by a Roche Pathologist involved in the development of algorithm. The training took place in multiple parts, including a group session, self-study (6 cases with consensus scores), mini test (6 cases with consensus scores), and a final proficiency test (12 cases with consensus scores). Reader Pathologists were required to complete a final proficiency test and achieve 90% overall percent agreement to consensus to ensure that they were comfortable and proficient in using the HER2 Dual ISH IA algorithm on Roche uPath enterprise software.Fig. 1

Study workflow.

Flowchart presenting the workflow of the validation studies.

Fig. 1

Yoder A., Inge L.J., Chen C.C., Marati V.R., Nguyen T.K., Zuiderveld K., Martin J., Gladden S., Miri M.S., Venugopal R., Lopez B., Ranger-Moore J, & Guetter C. (2022). Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer. Journal of Pathology Informatics, 13, 100116.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!